TD Cowen lowered the firm’s price target on BioLife Solutions to $25 from $29 and keeps an Outperform rating on the shares. The firm noted the company lowered 2023 across all business segments following a Q2 miss. Headwinds include a major customer de-stocking and budget tightening.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BLFS:
- BioLife Solutions Reports Second Quarter 2023 Financial Results, Updates Full Year 2023 Guidance and Provides Pro Forma First Half 2023 Financial Profile Excluding Freezer Business
- BLFS Upcoming Earnings Report: What to Expect?
- BioLife Solutions price target raised to $29 from $27 at Stephens
- Craig-Hallum starts BioLife Solutions at Buy with headwinds starting to subside
- BioLife Solutions initiated with a Buy at Craig-Hallum
